By Gina Shaw
Despite the recall of several different manufacturers’ formulations of extended-release (ER) metformin because of higher than acceptable levels of a potential carcinogen, experts said patients and providers should experience no significant disruptions in access to therapy, and they urged patients not to switch or discontinue their medication without consulting their doctor. Metformin is commonly used to control hyperglycemia in people with type 2 diabetes.
As of July 13, the